Investment case
Wolfspeed, Inc.
WOLF · 5 developments mapped · last assessed 2026-09-16
Market Ontology has mapped 5 macro, policy, and market developments to Wolfspeed, Inc. since 2026-08-21. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for WOLF yet, so no modelled value is shown. The WOLF valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run WOLF on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Wolfspeed, Inc. Completes Prepackaged Plan of Reorganization and Obtains Regulatory Approvals
Direct resolution of financial distress, improved capital structure, reduced debt burden, and potential for renewed operational focus.
· Moves financial risk premium, cost of debt, equity risk premium
- Main threat
Aehr Test Systems pivots 95% of fiscal 2026 revenue to AI and silicon photonics
Similar to ON, AEHR's strategic shift away from EV silicon carbide testing could reflect a more cautious outlook on the segment's growth, potentially impacting demand for Wolfspeed's core products.
· Moves ev silicon carbide market growth, utilization rates of new fabs
- Open question
Werewolf Therapeutics and Ambros Therapeutics announce merger agreement and concurrent $150 million private placement
Direct M&A transaction, equity dilution, strategic repositioning, and capital infusion.
· Moves future growth rates (synergies), cost of capital (risk profile), terminal multiple (strategic value)
What changed, by assumption
- 2026-09-16Wolfspeed, Inc. Completes Prepackaged Plan of Reorganization and Obtains Regulatory Approvals
- 2026-08-21Werewolf Therapeutics and Ambros Therapeutics announce merger agreement and concurrent $150 million private placement
- 2026-09-15Aehr Test Systems pivots 95% of fiscal 2026 revenue to AI and silicon photonics
- 2026-09-15Aehr Test Systems pivots 95% of revenue to AI processors and silicon photonics
- 2026-09-15Aehr Test Systems Shifts 95% of Revenue to AI Processors With $22M Follow-On Deal
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-09-16 | Net debt | Bearish | Liability-management transactions often reduce gross debt or push maturities out. | 0.70 |
| 2026-09-16 | Interest expense | Bearish | Tender/exchange extends maturity profile and typically lowers near-term interest expense. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-16 | Wolfspeed, Inc. Completes Prepackaged Plan of Reorganization and Obtains Regulatory Approvals | Bullish | 1-5y | 0.90 |
| 2026-09-15 | Aehr Test Systems pivots 95% of fiscal 2026 revenue to AI and silicon photonics | Bearish | 3-12m | 0.50 |
| 2026-09-15 | Aehr Test Systems pivots 95% of revenue to AI processors and silicon photonics | Bearish | 3-12m | 0.35 |
| 2026-09-15 | Aehr Test Systems Shifts 95% of Revenue to AI Processors With $22M Follow-On Deal | mixed | 3-12m | 0.25 |
| 2026-08-21 | Werewolf Therapeutics and Ambros Therapeutics announce merger agreement and concurrent $150 million private placement | mixed | 1-3m | 0.70 |